Coave Therapeutics strengthens its management team with the appointments of Catherine Mathis as Vice President of Regulatory Affairs and Julien Berger as Chief Legal Officer

PARIS, September 6, 2022 /PRNewswire/ — Coave Therapeutics (“Coave”), a clinical-stage biotechnology company focused on developing breakthrough gene therapies for CNS (central nervous system) and ocular diseases, today announced the appointment of Catherine MathisPharmD, as Vice President of Regulatory Affairs and Julien Bergeras Head of Legal Affairs.

Ms. Mathis will define and oversee the regulatory strategy and operations supporting the advancement of Coave’s programs. Mr. Berger will direct the legal activities of the Company and act as Corporate Secretary.

We are delighted to welcome Catherine and Julien to the Coave team. The newly created regulatory and legal positions demonstrate the company’s growth and the rapid progress we are making with our portfolio of novel coAAV gene therapies focused on CNS and ocular disease. Catherine brings extensive regulatory affairs experience for gene therapy-based programs that will be invaluable as we plan and execute our regulatory strategy for our three CNS programs targeting protein degradation. Julien has extensive experience in representing and advising companies in various legal activities at all stages of the pharmaceutical and biotechnology life cycle, supporting the implementation of operations while ensuring the protection of the rights and interests of companies. Catherine and Julien are key and timely additions to our leadership team and we look forward to working with them as we strive to transform the treatment of CNS diseases with our first-class gene therapy products,said Rodolphe ClervalCEO of Coave Therapeutics.

Catherine MathisPharmD
Catherine has more than 30 years of experience in clinical research and regulatory affairs in the pharmaceutical and biotechnology industries and has developed a solid expertise for the development of gene therapy from phase 1 to phase 3 in accordance with US and European regulations. . She has conducted numerous regulatory filings, IND meetings and scientific advice with the US Food and Drug Administration (FDA), European Medicines Agency (EMA) and other European National Competent Authorities.

Catherine spent 20 years at Transgene as Senior Director, Head of Regulatory Affairs setting up and leading the regulatory affairs department and overseeing global regulatory activities for the development of Transgene’s gene therapy products. Since Transgene, she has held management and regulatory positions at Voisin Consulting Life Sciences, TxCell (subsidiary of Sangamo Therapeutics), Elsalys Biotech and more recently Enterome.

Catherine holds a doctorate in pharmacy and a master’s degree in applied and fundamental toxicology from the University of Paris. She began her career in clinical research positions at Ipsen and Sanofi Pasteur.

Julien Berger
Julien brings to Coave nearly 20 years of experience in global, regional and local healthcare legal affairs, in corporate, commercial, medical, R&D, clinical operations and mergers and acquisitions. He joins Coave from Galapagos where he served as Director of Senior Legal Counsel, providing legal support and advice to its global teams.

Prior to Galapagos, Julien spent over 15 years in Genzyme’s legal team, most recently as General Counsel at Sanofi Genzyme following its acquisition. Julien developed and led the legal department of the French entity of Genzyme, supporting the growth of the activity in five therapeutic areas, managing the launch of products in addition to supporting the acquisition of Genzyme by Sanofi.

Julien is a graduate in business law from the universities of Lyons and Strasbourg.

About Coave Therapeutics

Coave Therapeutics is a clinical-stage biotechnology company focused on developing breakthrough gene therapies for CNS (central nervous system) and ocular diseases.

Coave Therapeutics’ next-generation AAV-Ligand (“ALIGATER”) conjugate platform enables targeted delivery and enhanced gene transduction to improve the efficacy of advanced gene therapies for rare diseases.

The company is advancing a pipeline of novel therapies targeting CNS and eye diseases where targeted gene therapy using chemically modified AAVs (coAAVs) has the potential to be most effective.

Coave Therapeutics, headquartered in Paris, France)is backed by leading international life sciences and strategic investors Seroba Life Sciences, Théa Open Innovation, eureKARE, Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital and Sham Innovation Santé/Turenne.

For more information, visit www.coavetx.com or follow us on LinkedIn

CONTACTS

Therapeutic Coave
Rodolphe ClervalCEO
[email protected]

MEDISTRAV Consulting
Sylvie Berrebi, Eleanor PerkinMark Swallow PhD
[email protected]
Tel: +44 203 928 6900

SOURCECoave Therapeutics

Comments are closed.